Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs

References

• Yu F, Du L, Ojcius DM, et al. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020 Mar;22(2):74–79. .
   PubMed Web of Science ®Google Scholar
• Senanayake SL. Drug repurposing strategies for COVID-19. Future Drug Dis. 2020;2(2): null.
   PubMedGoogle Scholar
• YF T, CS C, AA Y, et al. A Review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020;21:7.
   Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Diagnosis and treatment protocols of the novel coronavirus pneumonia (trial version 7). released 3 Mar, 2020. [cited 2020 Jul 18]. Available from:: http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm
   Google Scholar
• Comprehensive treatment and management of corona virus disease. expert consensus statement from Shanghai City. Chin J Infect Dis. 2019;38(3):134–138.
   Google Scholar
• Military expert group. Diagnosis and treatment of disease 2019 novel coronavirus infection suitable for Military support Hubei medical team. Chin J Tubercul Respirat Dis. 2020;43(4):285–287.
   Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929–936.
   PubMed Web of Science ®Google Scholar
• GM N, P H, SA M, et al. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: mechanistic insights into current COVID‑19 therapies (Review). Int J Mol Med. 2020;46(2):467–488.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020 May:22.
   Google Scholar
• Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Network Open. 2020 Apr 1;3(4):e208857.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Chen J, Liu D, Liu L, et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215–219.
   PubMedGoogle Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 May:27.
   Web of Science ®Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695–1704.
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. Bmj. 2020 May;14(369):m1849.
   Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Perry CM. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs. 2010 Oct 1; 70(14):1885–1915.
   PubMed Web of Science ®Google Scholar
• Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004 Sep;31(1):69–75.
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar;59(3):252–256.
   PubMed Web of Science ®Google Scholar
• de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014 Aug;58(8):4875–4884.
   PubMed Web of Science ®Google Scholar
• Kim UJ, Won EJ, Kee SJ, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455–459.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020 Mar 16;14(1):64–68.
   PubMed Web of Science ®Google Scholar
• Lim J, Jeon S, Shin HY, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci. 2020 Feb 17;35(6):e79.
   PubMed Web of Science ®Google Scholar
• Yan D, Liu XY, Zhu YN, et al. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J. 2020 Jul;56(1).
   Web of Science ®Google Scholar
• Ye XT, Luo YL, Xia SC, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3390–3396.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang H, Chen H, et al. Lianhua Qingwen capsule and interferon-α combined with lopinavir/ritonavir for the treatment of 30 COVID-19 patients. J Bengbu Med Coll. 2020;45(2):154–155.
   Google Scholar
• Zheng H, Su H, Wang S, et al. Thirteen cases of COVID patients treated by the combination of lopinavir/ritonavir tablets, atomized interferon α-2b and thymosin α1. Clin Res Pra. 2020;5(S1):36–38.
   Google Scholar
• Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 2020 Jul;81(1):e1–e5.
   Web of Science ®Google Scholar
• Wen CY, Xie ZW, Li YP, et al. [Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19: an observational cohort study]. Zhonghua Nei Ke Za Zhi. 2020 May 9;59:E012.
   PubMedGoogle Scholar
• Cheng CY, Lee YL, Chen CP, et al. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020 Jun;53(3):488–492.
   PubMedGoogle Scholar
• Nuffield department of population health. Statement from the chief investigators of the randomised evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir. released 29 June, 2020. [cited 2020 Jul 18]. Available from: https://www.recoverytrial.net/results/lopinavar-results.
   Google Scholar
• Liang J, Zheng T, Wang Q, et al. Safety Analysis of lopinavir/ritonavir tablets in 40 hospitalized patients with Coronavirus Disease 2019. Chin J Hosp Pharm. 2020;40(10):1086–1088. (in Chinese).
   Google Scholar
• Yang S, Liang J, Liu T, et al. Analysis of diarrhea associated with lopinavir-ritonavir for COVID-19 and its prevention. Med J West China. 2020;32(4):485–488.
   Google Scholar
• Gérard A, Romani S, Fresse A, et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. 2020 May:7.
   PubMed Web of Science ®Google Scholar
• Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020;6:28.
   PubMed Web of Science ®Google Scholar
• Sun Y, He X, Qiu F, et al. Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2013 May;51(5):423–432.
   PubMed Web of Science ®Google Scholar
• Liu L, Yuan L, Feng Y, et al. Clinical study on combined scheme of Lianhuaqingwen Capsules and abidole in the treatment for coranavirus disease 2019. Guangd Med J. 2020;(12):1–4.
   Google Scholar
• Xi J, Xiang S, Zhang H, et al. Clinical observation of arbidol combined with diammonium glycyrrhizinate in the treatment of COVID-19. Chin J Hosp Pharm. 2020;40(12):1287–1290. (in Chinese).
   Google Scholar
• Zang J, Peng F, Jiang Y, et al. Retrospective clinical study of efficacy and safety of arbidol hydrochloride in the treatment of corona virus disease 2019 with common type. ClinMed J. 2020;18(4):26–29.
   Google Scholar
• Xu P, Huang J, Fan Z, et al. Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study. Microbes Infect. 2020 May–Jun;22(4–5):200–205.
   Web of Science ®Google Scholar
• Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020 Jul;81(1):e21–e23.
   Web of Science ®Google Scholar
• Zhang JN, Wang WJ, Peng B, et al. Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study. Curr Med Sci. 2020 Jun;40(3):480–485.
   Web of Science ®Google Scholar
• Lian N, Xie H, Lin S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020 Jul;26(7):917–921.
   PubMed Web of Science ®Google Scholar
• Savarino A, Di Trani L, Donatelli I, et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006 Feb;6(2):67–69.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 1983 Jul 18;75:(1a):40–5.
   Web of Science ®Google Scholar
• Huang M, Tang T, Pang P, et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol. 2020 May 18;12(4):322–325.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732–739.
   Web of Science ®Google Scholar
• Painvin B, Guillot P, Verdier MC, et al. Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study. Intensive Care Med. 2020;8:1–2.
   Google Scholar
• Wu M, Wang B, Liu P, et al. Efficacy and safety of hydroxychloroquine combined with azithromycin in treatment of patients with refractory common coronavirus disease-19(COVID-19). Acad J Sec Mil Med Univ. 2020;41(6):612–615.
   Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar-Apr;34:101663.
   PubMed Web of Science ®Google Scholar
• Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020 May–Jun;35:101738.
   PubMed Web of Science ®Google Scholar
• Yu B, Li C, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020;1–7.
   PubMed Web of Science ®Google Scholar
• Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. Bmj. 2020 May;14(369):m1844.
   Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Jun 18;382(25):2411–2418.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. Jama. 2020 May 11;323(24):2493–2502.
   PubMed Web of Science ®Google Scholar
• Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. medRxiv. 2020 2020.07.15.20151852.
   Google Scholar
• Chorin E, Wadhwani L, Magnani S, et al. QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin. Heart Rhythm. 2020 May 11.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Zorzi A, Ceccato D, et al. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. Int J Cardiol. 2020 May 19.
   Web of Science ®Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 May 1.
   PubMed Web of Science ®Google Scholar
• Ramireddy A, Chugh H, Reinier K, et al. Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: implications for QT Interval Monitoring. J Am Heart Assoc. 2020 Jun 16;9(12):e017144.
   PubMed Web of Science ®Google Scholar
• Saleh M, Gabriels J, Chang D, et al. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 Mar 6;9:2.
   Web of Science ®Google Scholar
• EUROPEAN MEDICINES AGENCY. Summary on compassionate use for Remdesivir Gilead. Released 3 April, 2020. [cited 2020 Jul 18]. Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
   Google Scholar
• Zhang C, Chen S, Zhang J, et al. Analysis of chemical drugs applied for clinical trial for the treatment of COVID-19. Acta Pharma Sin. 2020;55(3):355–365.
   Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Jun 11;382(24):2327–2336.
   PubMed Web of Science ®Google Scholar
• Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother. 2018;26 Jan-Dec:2040206618764483.
   Google Scholar
• Irie K, Nakagawa A, Fujita H, et al. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19. Clin Transl Sci. 2020 May 31.
   PubMed Web of Science ®Google Scholar
• Lewczuk N, Zdebik A, Interferon Alpha BJ. 2a and 2b in Ophthalmology: A Review. J Interferon Cytokine Res. 2019 May;39(5): 259–272.
   PubMed Web of Science ®Google Scholar
• Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013 Dec;67(6):606–616.
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Jama. 2003 Dec 24;290(24):3222–3228.
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006 Sep;3(9):e343.
   PubMed Web of Science ®Google Scholar
• Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004 Mar;10(3):290–293.
   PubMed Web of Science ®Google Scholar
• Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013 Oct;19(10):1313–1317.
   PubMed Web of Science ®Google Scholar
• Falzarano D, de Wit E, Martellaro C, et al. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep. 2013;3:1686.
   PubMed Web of Science ®Google Scholar
• Mhashilkar AM, Biswas DK, LaVecchio J, et al. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. J Virol. 1997 Sep;71(9):6486–6494.
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020 Mar 18.
   PubMedGoogle Scholar
• Feng C, Yuantao H, Zhijie Z, et al. An urgent call for raising the scientific rigorousness of clinical trials on COVID-19. Chin J Epidemiol. 2020;41(3):301–302.
   Google Scholar